SPL 2.11% 9.3¢ starpharma holdings limited

Starpharma's Radiotherapeutics and Telix's Molecularly Targeted Radiation platform, page-2

  1. 3,349 Posts.
    lightbulb Created with Sketch. 793
    The reason no value is ascribed to SPL’s Dep pharmaceuticals is that they are still testing candidates pre-clinical. Whereas Telix have 5 candidates in clinical trials including two in Phase 3 and two in Phase 3....
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.